Norepinephrine transporter function and human cardiovascular disease

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 303, Issue 11, 2012, Pages

  Schroeder, C ^a   Jordan, J ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Autonomic nervous system; Blood pressure regulation; Cardiovascular; Norepinephrine; Norepinephrine transporter

Indexed keywords

NORADRENALIN TRANSPORTER; SIBUTRAMINE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RESPONSE; CONGESTIVE HEART FAILURE; DISEASE COURSE; ESSENTIAL HYPERTENSION; FAINTNESS; HUMAN; ISCHEMIC HEART DISEASE; NORADRENALIN RELEASE; POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME; PRIORITY JOURNAL; REVIEW; SYMPATHETIC TONE; TAKOTSUBO CARDIOMYOPATHY;

APPETITE DEPRESSANTS; AUTONOMIC NERVOUS SYSTEM; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CYCLOBUTANES; HUMANS; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; RISK FACTORS;

EID: 84870550547     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00492.2012     Document Type: Review

References (136)

1. Adamopoulos S, Kemp GJ, Thompson CH, Arnolda L, Brunotte F, Stratton JR, Radda GK, Rajagopalan B, Kremastinos DT, Coats AJ. The time course of haemodynamic, autonomic and skeletal muscle metabolic abnormalities following first extensive myocardial infarction in man. J Mol Cell Cardiol 31: 1913-1926, 1999.
2. Agostini D, Babatasi G, Scanu P, Lecluse E, Belin A, Quennelle F, Grollier G, Potier JC, Bouvard G. Value of cardiac scintigraphy with I123 meta-iodobenzylguanidine in congestive heart failure. A review. [In French.] Ann Cardiol Angeiol (Paris) 46: 293-302, 1997.
3. Alsidawi S, Muth J, Wilkin J. Adderall induced inverted-Takotsubo cardiomyopathy. Catheter Cardiovasc Interv 78: 910-913, 2011.
4. Arora S, Alfayoumi F, Srinivasan V. Transient left ventricular apical ballooning after cocaine use: is catecholamine cardiotoxicity the pathologic link? Mayo Clin Proc 81: 829-832, 2006.
5. Azevedo ER, Kubo T, Mak S, Al-Hesayen A, Schofield A, Allan R, Kelly S, Newton GE, Floras JS, Parker JD. Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity. Circulation 104: 2194-2199, 2001.
6. Barton DA, Dawood T, Lambert EA, Esler MD, Haikerwal D, Brenchley C, Socratous F, Kaye DM, Schlaich MP, Hickie I, Lambert GW. Sympathetic activity in major depressive disorder: identifying those at increased cardiac risk? J Hypertens 25: 2117-2124, 2007.
7. Bayles R, Baker E, Eikelis N, El-Osta A, Lambert G. Histone modifications regulate the norepinephrine transporter gene. Cell Cycle 9: 4600-4601, 2010.
8. Bayles R, Kn H, Lambert E, Baker EK, Agrotis A, Guo L, Jowett JB, Esler M, Lambert G, El-Osta A. Epigenetic modification of the norepinephrine transporter gene in postural tachycardia syndrome. Arterioscler Thromb Vasc Biol 32: 1910-1916, 2012.
9. Beau SL, Saffitz JE. Transmural heterogeneity of norepinephrine uptake in failing human hearts. J Am Coll Cardiol 23: 579-585, 1994.
10. Birkenfeld AL, Schroeder C, Boschmann M, Tank J, Franke G, Luft FC, Biaggioni I, Sharma AM, Jordan J. Paradoxical effect of sibutramine on autonomic cardiovascular regulation. Circulation 106: 2459-2465, 2002.
11. Birkenfeld AL, Schroeder C, Pischon T, Tank J, Luft FC, Sharma AM, Jordan J. Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients-sibutramine and blood pressure. Clin Auton Res 15: 200-206, 2005.
12. Bobb AJ, Addington AM, Sidransky E, Gornick MC, Lerch JP, Greenstein DK, Clasen LS, Sharp WS, Inoff-Germain G, Wavrant-De VF, Arcos-Burgos M, Straub RE, Hardy JA, Castellanos FX, Rapoport JL. Support for association between ADHD and two candidate genes: NET1 and DRD1. Am J Med Genet B Neuropsychiatr Genet 134B: 67-72, 2005.
13. Bohm M, La Rosée K, Schwinger RH, Erdmann E. Evidence for reduction of norepinephrine uptake sites in the failing human heart. J Am Coll Cardiol 25: 146-153, 1995.
14. Bonisch H, Runkel F, Roubert C, Giros B, Bruss M. The human desipramine-sensitive noradrenaline transporter and the importance of defined amino acids for its function. J Auton Pharmacol 19: 327-333, 1999.
15. Brush JE Jr, Eisenhofer G, Garty M, Stull R, Maron BJ, Cannon RO, III, Panza JA, Epstein SE, Goldstein DS. Cardiac norepinephrine kinetics in hypertrophic cardiomyopathy. Circulation 79: 836-844, 1989.
16. Bruss M, Kunz J, Lingen B, Bonisch H. Chromosomal mapping of the human gene for the tricyclic antidepressant-sensitive noradrenaline transporter. Hum Genet 91: 278-280, 1993.
17. Burgdorf C, von HK, Schunkert H, Kurowski V. Regional alterations in myocardial sympathetic innervation in patients with transient leftventricular apical ballooning (Tako-Tsubo cardiomyopathy). J Nucl Cardiol 15: 65-72, 2008.
18. Burniston JG, Ellison GM, Clark WA, Goldspink DF, Tan LB. Relative toxicity of cardiotonic agents: some induce more cardiac and skeletal myocyte apoptosis and necrosis in vivo than others. Cardiovasc Toxicol 5: 355-364, 2005.
19. Buttenschon HN, Kristensen AS, Buch HN, Andersen JH, Bonde JP, Grynderup M, Hansen AM, Kolstad H, Kaergaard A, Kaerlev L, Mikkelsen S, Thomsen JF, Koefoed P, Erhardt A, Woldbye DP, Borglum AD, Mors O. The norepinephrine transporter gene is a candidate gene for panic disorder. J Neural Transm 118: 969-976, 2011.
20. Carney RM, Freedland KE. Depression in patients with coronary heart disease. Am J Med 121: S20-S27, 2008.
21. Chang PC, van der Krogt JA, van BP. Demonstration of neuronal and extraneuronal uptake of circulating norepinephrine in the forearm. Hypertension 9: 647-653, 1987.
22. Christoph M, Ebner B, Stolte D, Ibrahim K, Kolschmann S, Strasser RH, Schon S. Broken heart syndrome: Tako Tsubo cardiomyopathy associated with an overdose of the serotonin-norepinephrine reuptake inhibitor Venlafaxine. Eur Neuropsychopharmacol 20: 594-597, 2010.
23. Cimarelli S, Sauer F, Morel O, Ohlmann P, Constantinesco A, Imperiale A. Transient left ventricular dysfunction syndrome: pathophysiological bases through nuclear medicine imaging. Int J Cardiol 144: 212-218, 2010.
24. Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med 108: 2-8, 2000.
25. Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, Murray KT, Quinn VP, Stein CM, Callahan ST, Fireman BH, Fish FA, Kirshner HS, O'Duffy A, Connell FA, Ray WA. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med 365: 1896-1904, 2011.
26. Currie G, Freel EM, Perry CG, Dominiczak AF. Disorders of blood pressure regulation-role of catecholamine biosynthesis, release, and metabolism. Curr Hypertens Rep 14: 38-45, 2012.
27. De RS, Beauloye C, De B, I, Vancraynest D, Gurne O, Gerber B, Hantson P. Tako-tsubo syndrome following nortriptyline overdose. Clin Toxicol (Phila) 46: 475-478, 2008.
28. Drakos SG, Athanasoulis T, Malliaras KG, Terrovitis JV, Diakos N, Koudoumas D, Ntalianis AS, Theodoropoulos SP, Yacoub MH, Nanas JN. Myocardial sympathetic innervation and long-term left ventricular mechanical unloading. JACC Cardiovasc Imaging 3: 64-70, 2010.
29. Eisenhofer G, Friberg P, Rundqvist B, Quyyumi AA, Lambert G, Kaye DM, Kopin IJ, Goldstein DS, Esler MD. Cardiac sympathetic nerve function in congestive heart failure. Circulation 93: 1667-1676, 1996.
30. Eisenhofer G, Saigusa T, Esler MD, Cox HS, Angus JA, Dorward PK. Central sympathoinhibition and peripheral neuronal uptake blockade after desipramine in rabbits. Am J Physiol Regul Integr Comp Physiol 260: R824-R832, 1991.
31. Esler M, Jackman G, Bobik A, Leonard P, Kelleher D, Skews H, Jennings G, Korner P. Norepinephrine kinetics in essential hypertension. Defective neuronal uptake of norepinephrine in some patients. Hypertension 3: 149-156, 1981.
32. Esler M, Jennings G, Lambert G, Meredith I, Horne M, Eisenhofer G. Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions. Physiol Rev 70: 963-985, 1990.
33. Esler M, Kaye D. Sympathetic nervous system activation in essential hypertension, cardiac failure and psychosomatic heart disease. J Cardiovasc Pharmacol 35: S1-S7, 2000.
34. Esler MD, Wallin G, Dorward PK, Eisenhofer G, Westerman R, Meredith I, Lambert G, Cox HS, Jennings G. Effects of desipramine on sympathetic nerve firing and norepinephrine spillover to plasma in humans. Am J Physiol Regul Integr Comp Physiol 260: R817-R823, 1991.
35. European Medicines Agency (E.M.A.). European Medicines Agency recommends suspension of marketing authorisations for sibutramine. 21 January 2010. (Internet Communication).
36. Fauchier L, Pierre B, de Labriolle A, Babuty D. Comparison of the beneficial effect of beta-blockers on mortality in patients with ischaemic or non-ischaemic systolic heart failure: a meta-analysis of randomised controlled trials. Eur J Heart Fail 9: 1136-1139, 2007.
37. Fleckenstein AE, Gibb JW, Hanson GR. Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity. Eur J Pharmacol 406: 1-13, 2000.
38. Freeman R, Wieling W, Axelrod FB, Benditt DG, Benarroch E, Biaggioni I, Cheshire WP, Chelimsky T, Cortelli P, Gibbons CH, Goldstein DS, Hainsworth R, Hilz MJ, Jacob G, Kaufmann H, Jordan J, Lipsitz LA, Levine BD, Low PA, Mathias C, Raj SR, Robertson D, Sandroni P, Schatz I, Schondorff R, Stewart JM, van Dijk JG. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 21: 69-72, 2011.
39. Freemantle N, Cleland J, Young P, Mason J, Harrison J. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 318: 1730-1737, 1999.
40. Gelernter J, Page GP, Stein MB, Woods SW. Genome-wide linkage scan for loci predisposing to social phobia: evidence for a chromosome 16 risk locus. Am J Psychiatry 161: 59-66, 2004.
41. Gold PW, Wong ML, Goldstein DS, Gold HK, Ronsaville DS, Esler M, Alesci S, Masood A, Licinio J, Geracioti TD Jr, Perini G, DeBellis MD, Holmes C, Vgontzas AN, Charney DS, Chrousos GP, McCann SM, Kling MA. Cardiac implications of increased arterial entry and reversible 24-h central and peripheral norepinephrine levels in melancholia. Proc Natl Acad Sci USA 102: 8303-8308, 2005.
42. Gujja KR, Aslam AF, Privman V, Tejani F, Vasavada B. Initial presentation of pheochromocytoma with Takotsubo cardiomyopathy: a brief review of literature. J Cardiovasc Med (Hagerstown) 11: 49-52, 2010.
43. Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, Cheetham TC, Quinn VP, Dublin S, Boudreau DM, Andrade SE, Pawloski PA, Raebel MA, Smith DH, Achacoso N, Uratsu C, Go AS, Sidney S, Nguyen-Huynh MN, Ray WA, Selby JV. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA 306: 2673-2683, 2011.
44. Haenisch B, Linsel K, Bruss M, Gilsbach R, Propping P, Nothen MM, Rietschel M, Fimmers R, Maier W, Zobel A, Hofels S, Guttenthaler V, Gothert M, Bonisch H. Association of major depression with rare functional variants in norepinephrine transporter and serotonin1A receptor genes. Am J Med Genet B Neuropsychiatr Genet 150B: 1013-1016, 2009.
45. Hahn MK, Mazei-Robison MS, Blakely RD. Single nucleotide polymorphisms in the human norepinephrine transporter gene affect expression, trafficking, antidepressant interaction, and protein kinase C regulation. Mol Pharmacol 68: 457-466, 2005.
46. Hahn MK, Robertson D, Blakely RD. A mutation in the human norepinephrine transporter gene (SLC6A2) associated with orthostatic intolerance disrupts surface expression of mutant and wild-type transporters. J Neurosci 23: 4470-4478, 2003.
47. Hahn MK, Steele A, Couch RS, Stein MA, Krueger JJ. Novel and functional norepinephrine transporter protein variants identified in attention-deficit hyperactivity disorder. Neuropharmacology 57: 694-701, 2009.
48. Harikrishnan KN, Bayles R, Ciccotosto GD, Maxwell S, Cappai R, Pelka GJ, Tam PP, Christodoulou J, El-Osta A. Alleviating transcriptional inhibition of the norepinephrine slc6a2 transporter gene in depolarized neurons. J Neurosci 30: 1494-1501, 2010.
49. Hasdemir C, Aydin HH, Celik HA, Simsek E, Payzin S, Kayikcioglu M, Aydin M, Kultursay H, Can LH. Transcriptional profiling of septal wall of the right ventricular outflow tract in patients with idiopathic ventricular arrhythmias. Pacing Clin Electrophysiol 33: 159-167, 2010.
50. Hauser W, Wolfe F, Tolle T, Uceyler N, Sommer C. The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis. CNS Drugs 26: 297-307, 2012.
51. Heusser K, Engeli S, Tank J, Diedrich A, Wiesner S, Janke J, Luft FC, Jordan J. Sympathetic vasomotor tone determines blood pressure response to long-term sibutramine treatment. J Clin Endocrinol Metab 92: 1560-1563, 2007.
52. Heusser K, Tank J, Diedrich A, Engeli S, Klaua S, Kruger N, Strauss A, Stoffels G, Luft FC, Jordan J. Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects. Clin Pharmacol Ther 79: 500-508, 2006.
53. Hippisley-Cox J, Pringle M, Hammersley V, Crown N, Wynn A, Meal A, Coupland C. Antidepressants as risk factor for ischaemic heart disease: case-control study in primary care. BMJ 323: 666-669, 2001.
54. Howell C, Wilson AD, Waring WS. Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases. Br J Clin Pharmacol 64: 192-197, 2007.
55. Imamura Y, Fukuyama T, Mochizuki T, Miyagawa M, Watanabe K. Prognostic value of iodine-123-metaiodobenzylguanidine imaging and cardiac natriuretic peptide levels in patients with left ventricular dysfunction resulting from cardiomyopathy. Jpn Circ J 65: 155-160, 2001.
56. Ito K, Sugihara H, Kinoshita N, Azuma A, Matsubara H. Assessment of Takotsubo cardiomyopathy (transient left ventricular apical ballooning) using 99mTc-tetrofosmin, 123I-BMIPP, 123I-MIBG and 99mTc-PYP myocardial SPECT. Ann Nucl Med 19: 435-445, 2005.
57. Jacob G, Shannon JR, Black B, Biaggioni I, Mosqueda-Garcia R, Robertson RM, Robertson D. Effects of volume loading and pressor agents in idiopathic orthostatic tachycardia. Circulation 96: 575-580, 1997.
58. Jafri SM. The effects of beta blockers on morbidity and mortality in heart failure. Heart Fail Rev 9: 115-121, 2004.
59. James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Shepherd GM, Rode RA, Renz CL. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 363: 905-917, 2010.
60. Jiang W, Davidson JR. Antidepressant therapy in patients with ischemic heart disease. Am Heart J 150: 871-881, 2005.
61. Jordan J, Scholze J, Matiba B, Wirth A, Hauner H, Sharma AM. Influence of Sibutramine on blood pressure: evidence from placebocontrolled trials. Int J Obes (Lond) 29: 509-516, 2005.
62. Jordan J, Shannon J, Robertson D. The physiological conundrum of hyperadrenergic orthostatic intolerance. Chin J Physiol 40: 1-8, 1997.
63. Jordan J, Shannon JR, Black BK, Paranjape SY, Barwise J, Robertson D. Raised cerebrovascular resistance in idiopathic orthostatic intolerance: evidence for sympathetic vasoconstriction. Hypertension 32: 699-704, 1998.
64. Kakuchi H, Sasaki T, Ishida Y, Komamura K, Miyatake K. Clinical usefulness of 123I meta-iodobenzylguanidine imaging in predicting the effectiveness of beta blockers for patients with idiopathic dilated cardiomyopathy before and soon after treatment. Heart 81: 148-152, 1999.
65. Kawai H, Mohan A, Hagen J, Dong E, Armstrong J, Stevens SY, Liang CS. Alterations in cardiac adrenergic terminal function and β-adrenoceptor density in pacing-induced heart failure. Am J Physiol Heart Circ Physiol 278: H1708-H1716, 2000.
66. Kitayama S, Dohi T. Norepinephrine transporter splice variants and their interaction with substrates and blockers. Eur J Pharmacol 479: 65-70, 2003.
67. Kohli U, Hahn MK, English BA, Sofowora GG, Muszkat M, Li C, Blakely RD, Stein CM, Kurnik D. Genetic variation in the presynaptic norepinephrine transporter is associated with blood pressure responses to exercise in healthy humans. Pharmacogenet Genomics 21: 171-178, 2011.
68. Kozlovskaia IIu, Shitov VN, Samoilenko LE, Merkulova IN, Staroverov II, Sergienko VB. Impairment of cardiac sympathetic function in patients with acute myocardial infarction and unstable angina. [In Russian.] Kardiologiia 44: 46-52, 2004.
69. Krantz DS, Whittaker KS, Francis JL, Rutledge T, Johnson BD, Barrow G, McClure C, Sheps DS, York K, Cornell C, Bittner V, Vaccarino V, Eteiba W, Parashar S, Vido DA, Merz CN. Psychotropic medication use and risk of adverse cardiovascular events in women with suspected coronary artery disease: outcomes from the Women's Ischemia Syndrome Evaluation (WISE) study. Heart 95: 1901-1906, 2009.
70. Ksiazek P, Buraczynska K, Buraczynska M. Norepinephrine transporter gene (NET) polymorphism in patients with type 2 diabetes. Kidney Blood Press Res 29: 338-343, 2006.
71. Kume T, Kawamoto T, Okura H, Toyota E, Neishi Y, Watanabe N, Hayashida A, Okahashi N, Yoshimura Y, Saito K, Nezuo S, Yamada R, Yoshida K. Local release of catecholamines from the hearts of patients with tako-tsubo-like left ventricular dysfunction. Circ J 72: 106-108, 2008.
72. Lambert E, Eikelis N, Esler M, Dawood T, Schlaich M, Bayles R, Socratous F, Agrotis A, Jennings G, Lambert G, Vaddadi G. Altered sympathetic nervous reactivity and norepinephrine transporter expression in patients with postural tachycardia syndrome. Circ Arrhythm Electrophysiol 1: 103-109, 2008.
73. Lee YJ, Hohoff C, Domschke K, Sand P, Kuhlenbaumer G, Schirmacher A, Freitag CM, Meyer J, Stober G, Franke P, Nothen MM, Fritze J, Fimmers R, Garritsen HS, Stogbauer F, Deckert J. Norepinephrine transporter (NET) promoter and 5=-UTR polymorphisms: association analysis in panic disorder. Neurosci Lett 377: 40-43, 2005.
74. Levine M, Truitt CA, O'Connor AD. Cardiotoxicity and serotonin syndrome complicating a milnacipran overdose. J Med Toxicol 7: 312-316, 2011.
75. Liang CS, Fan TH, Sullebarger JT, Sakamoto S. Decreased adrenergic neuronal uptake activity in experimental right heart failure. A chamberspecific contributor to beta-adrenoceptor downregulation. J Clin Invest 84: 1267-1275, 1989.
76. Licht CM, de Geus EJ, Seldenrijk A, van Hout HP, Zitman FG, van DR, Penninx BW. Depression is associated with decreased blood pressure, but antidepressant use increases the risk for hypertension. Hypertension 53: 631-638, 2009.
77. Lovecchio F, Kashani J. Isolated atomoxetine (Strattera) ingestions commonly result in toxicity. J Emerg Med 31: 267-268, 2006.
78. Machida M, Takechi S, Fujimoto T, Kakinoki S, Nomura A. Carvedilol improves uptake-1 in patients with systolic congestive heart failure. J Cardiovasc Pharmacol 59: 175-181, 2012.
79. Mann DL, Kent RL, Parsons B, Cooper G. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 85: 790-804, 1992.
80. Mayer AF, Schroeder C, Heusser K, Tank J, Diedrich A, Schmieder RE, Luft FC, Jordan J. Influences of norepinephrine transporter function on the distribution of sympathetic activity in humans. Hypertension 48: 120-126, 2006.
81. McCance AJ, Thompson PA, Forfar JC. Increased cardiac sympathetic nervous activity in patients with unstable coronary heart disease. Eur Heart J 14: 751-757, 1993.
82. Meier CR, Schlienger RG, Jick H. Use of selective serotonin reuptake inhibitors and risk of developing first-time acute myocardial infarction. Br J Clin Pharmacol 52: 179-184, 2001.
83. Meredith IT, Eisenhofer G, Lambert GW, Dewar EM, Jennings GL, Esler MD. Cardiac sympathetic nervous activity in congestive heart failure. Evidence for increased neuronal norepinephrine release and preserved neuronal uptake. Circulation 88: 136-145, 1993.
84. Merlet P, Piot O, Dubois-Rande JL, Loisance D, Castaigne A, Syrota A. Clinical use of metaiodobenzylguanidine imaging in cardiology. Q J Nucl Med 39: 29-39, 1995.
85. Moldovanova I, Schroeder C, Jacob G, Hiemke C, Diedrich A, Luft FC, Jordan J. Hormonal influences on cardiovascular norepinephrine transporter responses in healthy women. Hypertension 51: 1203-1209, 2008.
86. Monster TB, Johnsen SP, Olsen ML, McLaughlin JK, Sorensen HT. Antidepressants and risk of first-time hospitalization for myocardial infarction: a population-based case-control study. Am J Med 117: 732-737, 2004.
87. Monte S, Macchia A, Romero M, D'Ettorre A, Giuliani R, Tognoni G. Antidepressants and cardiovascular outcomes in patients without known cardiovascular risk. Eur J Clin Pharmacol 65: 1131-1138, 2009.
88. Morel O, Sauer F, Imperiale A, Cimarelli S, Blondet C, Jesel L, Trinh A, De PF, Ohlmann P, Constantinesco A, Bareiss P. Importance of inflammation and neurohumoral activation in Takotsubo cardiomyopathy. J Card Fail 15: 206-213, 2009.
89. Munch G, Rosport K, Bultmann A, Baumgartner C, Li Z, Laacke L, Ungerer M. Cardiac overexpression of the norepinephrine transporter uptake-1 results in marked improvement of heart failure. Circ Res 97: 928-936, 2005.
90. Nagamatsu H, Momose M, Kobayashi H, Kusakabe K, Kasanuki H. Prognostic value of 123I-metaiodobenzylguanidine in patients with various heart diseases. Ann Nucl Med 21: 513-520, 2007.
91. Neil CJ, Chong CR, Nguyen TH, Horowitz JD. Occurrence of Tako-Tsubo cardiomyopathy in association with ingestion of serotonin/noradrenaline reuptake inhibitors. Heart Lung Circ 21: 203-205, 2012.
92. Nickander KK, Carlson PJ, Urrutia RA, Camilleri M, Low PA. A screen of candidate genes and influence of beta2-adrenergic receptor genotypes in postural tachycardia syndrome. Auton Neurosci 120: 97-103, 2005.
93. Nonen S, Okamoto H, Fujio Y, Takemoto Y, Yoshiyama M, Hamaguchi T, Matsui Y, Yoshikawa J, Kitabatake A, Azuma J. Polymorphisms of norepinephrine transporter and adrenergic receptor alpha1D are associated with the response to beta-blockers in dilated cardiomyopathy. Pharmacogenomics J 8: 78-84, 2008.
94. Ogimoto A, Okayama H, Nagai T, Suzuki J, Inoue K, Nishimura K, Shigematsu Y, Tabara Y, Miki T, Higaki J. Impact of synergistic polymorphisms in adrenergic receptor-related genes and cardiovascular events in patients with dilated cardiomyopathy. Circ J 76: 2003-2008, 2012.
95. Ono K, Iwanaga Y, Mannami T, Kokubo Y, Tomoike H, Komamura K, Shioji K, Yasui N, Tago N, Iwai N. Epidemiological evidence of an association between SLC6A2 gene polymorphism and hypertension. Hypertens Res 26: 685-689, 2003.
96. Owen D, Du L, Bakish D, Lapierre YD, Hrdina PD. Norepinephrine transporter gene polymorphism is not associated with susceptibility to major depression. Psychiatry Res 87: 1-5, 1999.
97. Pacholczyk T, Blakely RD, Amara SG. Expression cloning of a cocaine-and antidepressant-sensitive human noradrenaline transporter. Nature 350: 350-354, 1991.
98. Packer M, Lee WH, Kessler PD, Gottlieb SS, Bernstein JL, Kukin ML. Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure. Circulation 75: IV80-IV92, 1987.
99. Parissis J, Fountoulaki K, Paraskevaidis I, Kremastinos DT. Sertraline for the treatment of depression in coronary artery disease and heart failure. Expert Opin Pharmacother 8: 1529-1537, 2007.
100. Pessoa PM, Xavier SS, Lima SL, Mansur J, de Almeida AS, Carvalho PA, Gutfilen B, da Fonseca BL. Assessment of takotsubo (ampulla) cardiomyopathy using iodine-123 metaiodobenzylguanidine scintigraphy. Acta Radiol 47: 1029-1035, 2006.
101. Prasad A, Madhavan M, Chareonthaitawee P. Cardiac sympathetic activity in stress-induced (Takotsubo) cardiomyopathy. Nat Rev Cardiol 6: 430-434, 2009.
102. Pratt LA, Brody DJ, Gu Q. Antidepressant use in persons aged 12 and over: United States, 2005-2008. NCHS Data Brief 1-8, 2011.
103. Ratcliffe S, Younus M, Hauben M, Reich L. Antidepressants that inhibit neuronal norepinephrine reuptake are not associated with increased spontaneous reporting of cardiomyopathy. J Psychopharmacol 24: 503-511, 2010.
104. Recchia FA, Giacca M. Targeted uptake-1 carrier to rescue the failing heart. Circ Res 97: 847-849, 2005.
105. Renner TJ, Nguyen TT, Romanos M, Walitza S, Roser C, Reif A, Schafer H, Warnke A, Gerlach M, Lesch KP. No evidence for association between a functional promoter variant of the Norepinephrine Transporter gene SLC6A2 and ADHD in a family-based sample. Atten Defic Hyperact Disord 3: 285-289, 2011.
106. Robertson D, Flattem N, Tellioglu T, Carson R, Garland E, Shannon JR, Jordan J, Jacob G, Blakely RD, Biaggioni I. Familial orthostatic tachycardia due to norepinephrine transporter deficiency. Ann NY Acad Sci 940: 527-543, 2001.
107. Rotondi F, Manganelli F, Carbone G, Stanco G. "Tako-tsubo" cardiomyopathy and duloxetine use. South Med J 104: 345-347, 2011.
108. Runkel F, Bruss M, Nothen MM, Stober G, Propping P, Bonisch H. Pharmacological properties of naturally occurring variants of the human norepinephrine transporter. Pharmacogenetics 10: 397-405, 2000.
109. Ryu SH, Lee SH, Lee HJ, Cha JH, Ham BJ, Han CS, Choi MJ, Lee MS. Association between norepinephrine transporter gene polymorphism and major depression. Neuropsychobiology 49: 174-177, 2004.
110. Sakuragi S, Tokunaga N, Okawa K, Kakishita M, Ohe T. A case of takotsubo cardiomyopathy associated with epileptic seizure: reversible left ventricular wall motion abnormality and ST-segment elevation. Heart Vessels 22: 59-63, 2007.
111. Schlaich MP, Lambert E, Kaye DM, Krozowski Z, Campbell DJ, Lambert G, Hastings J, Aggarwal A, Esler MD. Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and angiotensin neuromodulation. Hypertension 43: 169-175, 2004.
112. Schroeder C, Adams F, Boschmann M, Tank J, Haertter S, Diedrich A, Biaggioni I, Luft FC, Jordan J. Phenotypical evidence for a gender difference in cardiac norepinephrine transporter function. Am J Physiol Regul Integr Comp Physiol 286: R851-R856, 2004.
113. Schroeder C, Birkenfeld AL, Mayer AF, Tank J, Diedrich A, Luft FC, Jordan J. Norepinephrine transporter inhibition prevents tilt-induced pre-syncope. J Am Coll Cardiol 48: 516-522, 2006.
114. Schroeder C, Tank J, Boschmann M, Diedrich A, Sharma AM, Biaggioni I, Luft FC, Jordan J. Selective norepinephrine reuptake inhibition as a human model of orthostatic intolerance. Circulation 105: 347-353, 2002.
115. Selke KJ, Dhar G, Cohn JM. Takotsubo cardiomyopathy associated with titration of duloxetine. Tex Heart Inst J 38: 573-576, 2011.
116. Shannon JR, Flattem NL, Jordan J, Jacob G, Black BK, Biaggioni I, Blakely RD, Robertson D. Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. N Engl J Med 342: 541-549, 2000.
117. Shannon JR, Jordan J, Diedrich A, Pohar B, Black BK, Robertson D, Biaggioni I. Sympathetically mediated hypertension in autonomic failure. Circulation 101: 2710-2715, 2000.
118. Sherwood A, Blumenthal JA, Trivedi R, Johnson KS, O'Connor CM, Adams KF Jr, Dupree CS, Waugh RA, Bensimhon DR, Gaulden L, Christenson RH, Koch GG and Hinderliter AL. Relationship of depression to death or hospitalization in patients with heart failure. Arch Intern Med 167: 367-373, 2007.
119. Shibao C, Raj SR, Gamboa A, Diedrich A, Choi L, Black BK, Robertson D, Biaggioni I. Norepinephrine transporter blockade with atomoxetine induces hypertension in patients with impaired autonomic function. Hypertension 50: 47-53, 2007.
120. Simoes MV, Barthel P, Matsunari I, Nekolla SG, Schomig A, Schwaiger M, Schmidt G, Bengel FM. Presence of sympathetically denervated but viable myocardium and its electrophysiologic correlates after early revascularised, acute myocardial infarction. Eur Heart J 25: 551-557, 2004.
121. Simula S, Lakka T, Kuikka J, Laitinen T, Remes J, Kettunen R, Hartikainen J. Cardiac adrenergic innervation within the first 3 months after acute myocardial infarction. Clin Physiol 20: 366-373, 2000.
122. Slavikova J, Kuncova J, Topolcan O. Plasma catecholamines and ischemic heart disease. Clin Cardiol 30: 326-330, 2007.
123. Smoller JW, Allison M, Cochrane BB, Curb JD, Perlis RH, Robinson JG, Rosal MC, Wenger NK, Wassertheil-Smoller S. Antidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women in the Women's Health Initiative study. Arch Intern Med 169: 2128-2139, 2009.
124. Sogawa C, Mitsuhata C, Kumagai-Morioka K, Sogawa N, Ohyama K, Morita K, Kozai K, Dohi T, Kitayama S. Expression and function of variants of human catecholamine transporters lacking the fifth transmembrane region encoded by exon 6. PLoS One 5: e11945, 2010.
125. Stober G, Nothen MM, Porzgen P, Bruss M, Bonisch H, Knapp M, Beckmann H, Propping P. Systematic search for variation in the human norepinephrine transporter gene: identification of five naturally occurring missense mutations and study of association with major psychiatric disorders. Am J Med Genet 67: 523-532, 1996.
126. Strempel S, Schroeder C, Hemmersbach R, Boese A, Tank J, Diedrich A, Heer M, Luft FC, Jordan J. Norepinephrine transporter inhibition alters the hemodynamic response to hypergravitation. J Appl Physiol 104: 756-760, 2008.
127. Tagawa M, Nakamura Y, Ishiguro M, Satoh K, Chinushi M, Kodama M, Aizawa Y. Transient left ventricular apical ballooning developing after the Central Niigata Prefecture Earthquake: two case reports. J Cardiol 48: 153-158, 2006.
128. Tank J, Schroeder C, Diedrich A, Szczech E, Haertter S, Sharma AM, Luft FC, Jordan J. Selective impairment in sympathetic vasomotor control with norepinephrine transporter inhibition. Circulation 107: 2949-2954, 2003.
129. Tata LJ, West J, Smith C, Farrington P, Card T, Smeeth L, Hubbard R. General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction. Heart 91: 465-471, 2005.
130. Vinetti M, Haufroid V, Capron A, Classen JF, Marchandise S, Hantson P. Severe acute cardiomyopathy associated with venlafaxine overdose and possible role of CYP2D6 and CYP2C19 polymorphisms. Clin Toxicol (Phila) 49: 865-869, 2011.
131. Weeke P, Jensen A, Folke F, Gislason GH, Olesen JB, Andersson C, Fosbol EL, Larsen JK, Lippert FK, Nielsen SL, Gerds T, Andersen PK, Kanters JK, Poulsen HE, Pehrson S, Kober L, Torp-Pedersen C. Antidepressant use and risk of out-of-hospital cardiac arrest: a nationwide case-time-control study. Clin Pharmacol Ther 92: 72-79. 2012.
132. Whang W, Kubzansky LD, Kawachi I, Rexrode KM, Kroenke CH, Glynn RJ, Garan H, Albert CM. Depression and risk of sudden cardiac death and coronary heart disease in women: results from the Nurses' Health Study. J Am Coll Cardiol 53: 950-958, 2009.
133. Wichter T, Schafers M, Rhodes CG, Borggrefe M, Lerch H, Lammertsma AA, Hermansen F, Schober O, Breithardt G, Camici PG. Abnormalities of cardiac sympathetic innervation in arrhythmogenic right ventricular cardiomyopathy: quantitative assessment of presynaptic norepinephrine reuptake and postsynaptic beta-adrenergic receptor density with positron emission tomography. Circulation 101: 1552-1558, 2000.
134. Xiong GL, Jiang W, Clare R, Shaw LK, Smith PK, Mahaffey KW, O'Connor CM, Krishnan KR, Newby LK. Prognosis of patients taking selective serotonin reuptake inhibitors before coronary artery bypass grafting. Am J Cardiol 98: 42-47, 2006.
135. Yamabe H, Hanaoka J, Funakoshi T, Iwahashi M, Takeuchi M, Saito K, Kawashima S, Yokoyama M. Deep negative T waves and abnormal cardiac sympathetic image (123I-MIBG) after the Great Hanshin Earthquake of 1995. Am J Med Sci 311: 221-224, 1996.
136. Zolk O, Ott C, Fromm MF, Schmieder RE. Effect of the rs168924 single-nucleotide polymorphism in the SLC6A2 catecholamine transporter gene on blood pressure in Caucasians. J Clin Hypertens (Greenwich) 14: 293-298, 2012.